Current perspective – Trastuzumab

descriptionPublicationkeyboard_double_arrow_right Article 01 Jan 2009 United Kingdom English Publisher:Elsevier BVJournal:European Journal of Cancer, volume 45, pages 12-18 (issn: 0959-8049,

Copyright policy )

Authors: Hall, P.S.; Cameron, D.A.;

doi: 10.1016/j.ejca.2008.10.013

pmid: 19042123

Current perspective – Trastuzumab

- Summary
- Subjects
- Metrics

Abstract

This article will review the available clinical data on the efficacy of trastuzumab in the treatment of both early advanced breast cancer.

Country

United Kingdom

Related Organizations

University of Leeds
United Kingdom
White Rose Consortium: University of Leeds; University of Sheffield; University of York
United Kingdom

Keywords

Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Genes, erbB-2, Trastuzumab, Antibodies, Monoclonal, Humanized, Treatment Outcome, Chemotherapy, Adjuvant, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Humans, Female, Neoplasm Recurrence, Local, Follow-Up Studies

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	51
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 1%